An increasing number of patients in our country use oral anticoagulants for the prophylaxis and treatment of thromboembolic events. The
cornerstone of these groups of agents is warfarin, a vitamin K antagonist, which has been the single alternative used by oral route for several
years. However, due to warfarin’s late onset and long lasting action and the intense interactions with food and drugs, newer oral anticoagulants
have emerged in the market in recent years. Dabigatran, rivaroxaban and apixaban are the novel agents used in our country.
Those drugs should be regulated in the perioperative period when patients receiving oral anticoagulants are referred for dental interventions.
The interruption of agents may result in lethal consequences of thromboembolic events, while continuing raises the risk of bleeding. This review
outlines the various properties of the oral anticoagulants and the most recent recommendations and guidelines regarding the management of
dental patients taking these medications.